A phase I trial to evaluate Antibody-Coupled T-cell Receptor (ACTR) platform in Non-Hodgkin Lymphoma (NHL) patients who have failed to respond or relapsed following treatment with chemotherapy plus rituximab

Trial Profile

A phase I trial to evaluate Antibody-Coupled T-cell Receptor (ACTR) platform in Non-Hodgkin Lymphoma (NHL) patients who have failed to respond or relapsed following treatment with chemotherapy plus rituximab

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs ATTCK 20 (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2015 New trial record
    • 14 Dec 2015 According to an Unum Therapeutics media release, the company plans to file an IND with the US FDA and to begin clinical testing in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top